Bile Acids in Hepatobiliary Disease

Preface. List of Contributors. <strong>1.</strong> Introduction; T.C. Northfield. <strong>Section I: Cholestatic Liver Disease: Physiology, Pathogenesis and</strong> <strong>Epidemiology.</strong> <strong>2.</strong> Cellular and Molecular Mechanisms of Bile Salt Transport in Health and Disease; J.L. Boyer. <strong>3.</strong> Biochemical Aspects; J. Reichen. <strong>4.</strong> Immunological Aspects; M.F. Bassendine. <strong>Section II:</strong> <strong>Bile Acid Therapy.</strong> <strong>5.</strong> Optimum Dose of UDCA in Primary Biliary Cirrhosis (PBC); A. Verma. <strong>6.</strong> Ursodeoxycholic Acid - An Immunomodulator in Primary Biliary Cirrhosis? A.G. Lim, et al. <strong>Section</strong> <strong>III: Clinical Trials.</strong> <strong>7.</strong> Primary Biliary Cirrhosis: Long-Term Management with Ursodeoxycholic Acid; J. Heathcote. <strong>8.</strong> Management of Patients with Primary Schlerosing Cholangitis; A. Stiehl. <strong>9.</strong> Genetic Aspects; R. Thompson. <strong>10.</strong> Congenital Defects in Bile Acid Synthesis Cause A Spectrum of Diseases Manifest as Severe Cholestasis, Neurological Disease, and Fat-Soluble Vitamin Malabsorption; K.D.R. Setchell. <strong>11.</strong> Cystic Fibrosis of the Liver; C. Colombo. <strong>12.</strong> Canalicular Secretion of Lysyl-fluorescein Bile Acids in 17beta-estradiol Glucuronide (17betaEG) Induced Cholestasis: Protective Effect of S-andenosyl-L-methionine (SAMe); P. Milkiewicz. <strong>Section IV: Alcoholic and Other Liver Diseases. 13.</strong> Ethanol Metabolism; T. Peters. <strong>14.</strong> Alcohol Abuse and Abstinence; H. Ghodse. <strong>15.</strong> Pathogenesis of Alchoholic Liver Disease; C.S. Lieber. <strong>16.</strong> Clinical Aspects of Alcoholic Liver Disease; R. Williams. <strong>Section V:</strong> Bile Acid Therapy.</strong> <strong>17.</strong> Effect on Liver Function; P. Hayes. <strong>18.</strong> Fibrosis Markers and Ursodeoxycholic Acid; J.M.C. Stenner. <strong>19.</strong> Urdodeoxycholic Acid for Treatment of Chronic Hepatitis C: An `Interferon Sparing' Effect; A. Lanzini. <strong>Section VI: Cholesterol</strong> <strong>Gallstone Disease.</strong> <strong>20.</strong> Pathogenesis of Cholesterol Gallstone Disease: Role of the Liver; M.C. Carey. <strong>21.</strong> Pathogenesis of Gallstones: Events in Bile; T. Gilat. <strong>22.</strong> Role of the Gallbladder in the Pathogenesis of Gallstone Disease; R.P. Jazrawi, et al. <strong>23.</strong> The Role of the Large Intestine in Cholesterol Gallstone Formation; K.W. Heaton. <strong>24.</strong> The Octreotide Model; R.H. Dowling. <strong>Section VII: Therapy.</strong> <strong>25.</strong> Oral Bile Acid Therapy; E. Roda. <strong>26.</strong> Cholesterol Solvents for Topical Gallstone Dissolution; U. Leuschner. <strong>27.</strong> Mechanisms of Dissolution of Cholesterol Gallstones; H.A. Ahmed. <strong>28.</strong> Extracorporeal Shock-wave Lithotripsy of Gallstones; G.H. Sauter. <strong>29.</strong> Management of Gallstone Recurrence; T.C. Northfield. <strong>30.</strong> Laparoscopic Cholecystectomy; A. Johnson. <strong>31.</strong> Comparison of UDCA With Combination Therapy of UDCA Plus CDCA on Gallstone Dissolution: A Randomised Multicentre Trial; M.L. Petroni. <strong>Section VIII: Other Conditions. 32.</strong> Role of Bile Acids in Colonic Neoplasia: Experimental Animal Studies; C.A. Einarsson. <strong>33.</strong> Role of Bile Acids in Colonic Neoplasia &endash; Human Studies; M. Stellini. <strong>Section IX: Chronic Pancreatitis.</strong> <strong>34.</strong> Role of Bile Acids in Pancratic Steatorrhea; P. Zentler-Munro. <strong>35.</strong> Impaired Uptake of Long-chain Fatty Acids Contributes to Fat Malabsorption in Paediatric Patients with Cystic Fibrosis; H.J. Verkade. <strong>36.</strong> Bile Acid Science (Cholanology) at the Dawn of a New Millennium: Past Progress and Challenges for the Future; A.F. Hofmann. Index.